Chemotherapy for advanced pancreatic cancer: It may no longer be ignored

Citation
S. Cascinu et al., Chemotherapy for advanced pancreatic cancer: It may no longer be ignored, ANN ONCOL, 10(1), 1999, pp. 105-109
Citations number
34
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
ANNALS OF ONCOLOGY
ISSN journal
09237534 → ACNP
Volume
10
Issue
1
Year of publication
1999
Pages
105 - 109
Database
ISI
SICI code
0923-7534(199901)10:1<105:CFAPCI>2.0.ZU;2-#
Abstract
Two case histories are reported here in which a chemotherapeutic approach i mproved the clinical conditions of patients with advanced pancreatic cancer . Until recently, chemotherapy was considered ineffective in pancreatic can cer, and most oncologists treated these patients with best-supportive-care only Enthusiasm for systemic therapy of advanced pancreatic cancer is again growing, spurred by the advent of new drugs and new treatment endpoints su ch as life quality and symptom palliation. Gemcitabine, the most intensivel y-investigated new drug in pancreatic cancer: has shown an advantage in bot h survival and clinical benefit over that of 5-fluorouracil (5-FU). Other n ew drugs such as taxanes have shown interesting levels of activity, and are deserving of further evaluation. Although these results are Ear from concl usive and are only partially satisfactory, they represent a significant ste p forward in the treatment of advanced pancreatic cancer.